Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
Date:2/17/2009

, an increase of 3% that resulted primarily from higher short-term investment balances. For the full year 2008, total other income was $15.5 million, compared to $12.3 million in the prior year period, an increase of 26% that also resulted from higher short-term investment balances.

Gen-Probe continues to have a strong balance sheet. As of December 31, 2008, the Company had $505.2 million of cash, cash equivalents and short-term investments, and no debt. In the fourth quarter of 2008, the Company repurchased approximately 1.5 million shares of its common stock for $65 million. For the full year 2008, Gen-Probe generated net cash of $178.3 million from its operating activities, compared to the Company's net income of $107.0 million.

2009 Financial Guidance

Gen-Probe provided its initial 2009 financial guidance via a press release issued on January 27, 2009.

"We expect 2009 to be another year of solid underlying earnings growth for Gen-Probe, although previously disclosed non-recurring items that added approximately $32 million of revenue and $0.34 of EPS will make comparisons to 2008 difficult," said Herm Rosenman, the Company's senior vice president of finance and chief financial officer.

Gen-Probe's 2009 guidance excludes revenue and expense associated with the pending Tepnel acquisition, which is expected to close in the second quarter, as well as any incremental revenue from the PROCLEIX ULTRIO assay in the United States. For the full year 2009, the Company expects the following on a GAAP basis:

                                        2009 Guidance
    Total revenues              $460 million to $490 million
    Product gross margins                   69-72%
    R&D expenses                            20-22%
    Marketing and sales expenses            10-11%
    G&A expenses                            10-11%
    Tax ra
'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
2. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
3. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
4. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
5. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
8. Gen-Probe to Webcast Two Upcoming Investor Presentations
9. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
10. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
11. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 The 2013 edition of ... chemical listings, appellate decisions, litigation and settlement trends, ... compliance with California's Proposition 65. , The Handbook ... regulations, history and trends impacting California's Proposition 65. ... of the series which adds approximately 200 pages ...
(Date:7/31/2014)... On October 10, at the Palmer ... Applied Research Foundation, in collaboration with the University ... mesothelioma conference geared to patients and ... to mesothelioma and presented by local and regional ... include imaging, genetics, first-line therapies, surgery, chemotherapy, radiation ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/31/2014)... Nashville, TN (PRWEB) July 31, 2014 ... TN was one of the first surgeons in the United ... the iStent, the smallest medical device ever approved ... the first surgeons to recognize the benefits of using a ... patients with glaucoma. Dr. Shofner and his colleagues now recognize ...
(Date:7/31/2014)... 2014 The vineyards are lush, and the ... And, to celebrate, folks are gearing up for the annual ... and 7, 2014 along the Leelanau Peninsula Wine Trail ... or run through the vineyards start-ing at 9:00 a.m. on ... unique course between rows of grapevines offers an experience like ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2
... , TUESDAY, Feb. 21 (HealthDay News) -- Insulin production may ... according to a new study. The findings add to ... the onset of the disease is longer than previously believed, ... thought that beta cell function completely ceased in patients with ...
... recession was the longest and most severe since World War ... at the slowest rate in over 50 years, suggesting that ... that these cut backs were not limited to Americans who ... at the University of North Carolina at Chapel Hill School ...
... , New Rochelle, NY, February 21, 2012Faith-based advocacy has ... obesity, but evidence is needed to support this assertion ... policy can contribute to promoting permanent lifestyle changes. This ... journal Childhood Obesity celebrating the second anniversary ...
... News) -- Researchers who traced the evolution of a ... livestock to humans say their findings highlight the dangers ... The international team of scientists studied methicillin-resistant Staphylococcus ... livestock-associated MRSA, which most often infects people with direct ...
... By reformulating the common cancer drug imatinib (Gleevec), researchers ... step toward improving the effectiveness of chronic pain management ... Texas MD Anderson Cancer Center. Narcotics such as ... time, tolerance to the pain-relieving effects of these drugs ...
... rescues malignant cells from destruction by extending the protective caps ... triggers resistance pathways that allow cancer to survive and spread, ... . "Telomerase is overexpressed in many advanced cancers, but ... understand what it does and how it does it," said ...
Cached Medicine News:Health News:Type 1 Diabetes May Develop More Slowly Than Thought 2Health News:Recession and high co-pays tied to fewer colonoscopy screenings among people with health insurance 2Health News:Childhood obesity -- can faith-based organizations make a difference? 2Health News:Pig-to-Human 'Superbug' May Be Due to Animal Antibiotics 2Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 3Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 4
(Date:7/31/2014)... , Indien, August 1, 2014 ... BioQuiddity Inc. gaben heute bekannt, vor kurzem ... Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen eine ... Gebiet der Europäischen Union und weiterer europäischer ... versehene und mit Ropivacain gefüllte OneDose ReadyfusOR ...
(Date:7/31/2014)... 31, 2014  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... STXS ) announced today the appointment of ... (EMEA) to lead the Company,s EMEA operations and sales ... utilization of its Niobe® Remote Magnetic Navigation System and ... P. Kaminski, President and CEO of Stereotaxis. ...
... Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial ... For the third quarter of 2010, the Company reported net income ... loss of $8.2 million, or $0.21 per share, for the same ... the Company reported a net loss of $10.5 million, or $0.20 ...
Cached Medicine Technology:Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 2Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 3Neurocrine Biosciences Reports Third Quarter 2010 Results 2Neurocrine Biosciences Reports Third Quarter 2010 Results 3Neurocrine Biosciences Reports Third Quarter 2010 Results 4Neurocrine Biosciences Reports Third Quarter 2010 Results 5Neurocrine Biosciences Reports Third Quarter 2010 Results 6Neurocrine Biosciences Reports Third Quarter 2010 Results 7Neurocrine Biosciences Reports Third Quarter 2010 Results 8
Inquire...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
Medicine Products: